Quanta Fluid Solutions said Tuesday it won a $2.9 million (UK £1.85 million) grant from the U.K.’s National Institute for Health Research to support a new nocturnal hemodialysis product.
The grant will go towards the development of a new dialysis machine concept that is specifically designed for nocturnal use, Quanta said. With the funds, Quanta is slated to develop a series of new technologies to optimize the delivery of nocturnal dialysis.
“We are excited to have been awarded i4i funding from the NIHR. This will enable us to develop our product offering in promising new directions and to investigate the potential of new technologies for a nocturnal system designed to bring even greater benefits to renal patients. The i4i award is a validation of Quanta’s vision and capacity for innovation in dialysis technologies. We look forward to working with Sheffield University and Europlaz Technologies in developing this new concept,” CEO John Milad said in a press release.
Quanta will be collaborating with William Zimmerman of Sheffield University’s department of chemical and biological engineering and Europlaz Technologies for the project. The team at Sheffield University will contribute towards multi-physics modeling of haemodialysis and Europlaz will aid in the development of technologies to be used in designing disposable cartridges for the system.
“We believe that, with NIHR funding and the work Quanta is already doing in the dialysis space, SC+ has the potential to change the way dialysis patients are treated. Our award validates the unique positioning of i4i in de-risking early stage, innovative technologies for later stage investment. The addition of a nocturnal system would give patients even more flexibility and control over their treatment options and we are looking forward to seeing the results of this promising project,” NIHR i4i program director Martin Hunt said in prepared remarks.
Nocturnal dialysis is generally a long overnight treatment that more accurately imitates natural kidney function and is gentler on the body, Quanta said. Frequent nocturnal dialysis has been shown to increase 5-year survivability comparable to donor transplants, the company said.
